ABSTRACT
Cancer is an abnormal and uncontrolled growth of cells that spreads through cell division. There are different types of medicines available to treat cancers, but no drug is found to be fully effective and safe for humans. The major problem involved in the cancer treatments is the toxicity of the established drug and their side effects. Medicinal plants are used as folk medicines in Asian and African populations for thousands of years. 60% of the drugs for treating cancer are derived from plants. More than 3000 plants have anticancer activity. The present review aims at the study of a broad spectrum survey of plants having anticancer components for different type of cancers. This article consists of 364 medicinal plants and their different parts as potential Source of Anticancer Agents.
El cáncer es un crecimiento anormal y descontrolado de células que se disemina a través de la división celular. Hay diferentes tipos de medicamentos disponibles para tratar el cáncer, pero no se ha encontrado ningún medicamento que sea completamente efectivo y seguro para los seres humanos. El principal problema involucrado en los tratamientos del cáncer es la toxicidad del fármaco establecido y sus efectos secundarios. Las plantas medicinales se utilizan como medicinas populares en poblaciones asiáticas y africanas durante miles de años. El 60% de los medicamentos para el tratamiento del cáncer se derivan de plantas. Más de 3000 plantas tienen actividad anticancerígena. La presente revisión tiene como objetivo el estudio de un estudio de amplio espectro de plantas que tienen componentes anticancerígenos para diferentes tipos de cánceres. Este artículo consta de 364 plantas medicinales y sus diferentes partes como fuente potencial de agentes anticancerígenos.
Subject(s)
Plants, Medicinal/chemistry , Anticarcinogenic Agents/pharmacology , Phytochemicals/analysis , Cell Line, Tumor/drug effects , Phytochemicals/pharmacologyABSTRACT
Though prehypertension has recently been considered as a risk factor for cardiovascular accidents, the pathophysiological mechanism that causes the development of prehypertension in normotensive subjects has not been fully elucidated. Therefore, the present study was conducted to assess the sympathovagal imbalance in prehypertensives and normotensives by spectral analysis of heart rate variability (HRV) to understand the nature of change in autonomic balance in this dysfunction. Body mass index (BMI), waist-hip ratio (WHR), basal heart rate (BHR), blood pressure (BP), rate-pressure product (RPP) and spectral indices of HRV such as total power (TP), normalized low frequency power (LFnu), normalized high frequency power (HFnu), ratio of low frequency power to high frequency power (LF-HF ratio), mean heart rate (mean RR), square root of the mean squared differences of successive normal to normal intervals; (RMSSD), the number of interval differences of successive NN intervals greater than 50 ms (NN50) and the proportion derived by dividing NN50 by the total number of NN intervals (pNN50) were assessed in two groups of young subjects: normotensives (n=68) and prehypertensives (n=66). Sympathovagal balance (SVB) was analyzed and correlated with BMI, WHR, BHR, BP and RPP in both the groups. It was observed that autonomic imbalance in prehypertensives was due to increase in both sympathetic activity and vagal inhibition. LF-HF ratio, the sensitive indicator of SVB was significantly correlated with BMI, WHR, BHR, BP and RPP in prehypertensive subjects. It was concluded that vagal inhibition might be important in the critical alteration of sympathovagal balance in the development of prehypertension in young normotensive subjects.